{"created":"2022-02-22T03:32:44.875891+00:00","id":2015938,"links":{},"metadata":{"_buckets":{"deposit":"7f89b81b-933d-4adc-b89b-d7575f8b2846"},"_deposit":{"id":"2015938","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2015938"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02015938","sets":["1642838163960:1642838198944:1642838199408:1642838207689","1642838403551:1642838412624"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"[総説］北米における感性脳腫癖に対する遺伝子泊癖の状況 : 文部省在外研究報告","subitem_title_language":"ja"},{"subitem_title":"Report of the ministry of education reserearch program on the present state of gene therapy for malignant brain tumor in North America","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"宮城, 航一","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"Miyagi, Koichi","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"琉球医学会","subitem_rights_language":"ja"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"brain tumor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"gene therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"glioblastoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"viral vector","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"One of the most difficult problem in malignant glioma therapy is the elimination of invasive glioma cell in normal brain tissue. The solution to this problem is the application of gene therapy. For further research and developement of this gene therapy, I had an oppotunity to visit the NIH and other Institutes in North America. NIH had a clinical protocol of gene therapy for malignant glioma. This clinical protocol was started in December 1992. The result has not yet been reported. Recombinant retrovirus producer cell was injected stereotactically in to the brain tumor. Seven days later ganciclovir treatment was given for 14 days. For two cases, the brain tumor was reoperated few days after the producer cell injection, that is before ganciclovir therapy. Percentage of target gene transduced cells was less than 0.2%. However for 5 out of 16 lesions, tumor size became less than 50% of pre-treatment size. They concluded that bystander effect contributed to the decrease in the tumor size. There was neither toxicity nor replication of competent retrovirus from peripheral blood lymphocyte. Genetic Therapy Incorporation (GTI) and Sandoz Pharma Ltd have extended their phase II protocol to 10 Institutes each in the U.S.A, Europe and Canada. Suicide gene therapy (HSVtk/GCV system) and immuno-modified gene therapy are usually applied to malignant tumor. The genes ofcytokine, adhesion molucles or major histocompatibility complex are introduced into the tumor-infiltrated lymphocyte, lymphokineactivated lymphocyte or tumor cell. Target gene transduced lymphocytes secrete cytokines and attract the cytotoxic T lymphocyte into the tumor tissue. On the other hand, transduced tumor cells are used as the tumor vaccine. Usually, suicide gene therapy is applied to brain tumor, whereas the tumor vaccines are applied to melanoma and renal cell carcinoma, because these tumors have a high antigenicity. Unfortunately, NIH clinical results reveal that the transduction ratio of recombinant retroviral vector into the glioma cells is low. Therefore, the most important area in the gene therapy for malighant glioma is to develop a method to transfer the target gene into the infiltrated glioma cell. For clinical application, it is advisable to obtain the vector producer cells from GTI since the confirmation of safety and quality of the vector is extremely expensive. However, it is better for us to develop our own basic research program.","subitem_description_type":"Other"},{"subitem_description":"論文","subitem_description_type":"Other"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"琉球医学会","subitem_publisher_language":"ja"},{"subitem_publisher":"Ryukyu Medical Association","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"1346888X","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"0289-1530","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"AN10369445","subitem_source_identifier_type":"NCID"}]},"item_1617186941041":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_source_title":"琉球医学会誌 = Ryukyu Medical Journal","subitem_source_title_language":"ja"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1996","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"15","bibliographicPageStart":"11","bibliographicVolumeNumber":"16"}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"v16p11.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2015938/files/v16p11.pdf"},"version_id":"fc95b8f2-2907-4610-af28-02407dfa5faa"}]},"item_title":"[総説］北米における感性脳腫癖に対する遺伝子泊癖の状況 : 文部省在外研究報告","item_type_id":"15","owner":"1","path":["1642838207689","1642838412624"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-07-02"},"publish_date":"2010-07-02","publish_status":"0","recid":"2015938","relation_version_is_last":true,"title":["[総説］北米における感性脳腫癖に対する遺伝子泊癖の状況 : 文部省在外研究報告"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2022-10-31T07:47:17.283548+00:00"}